These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27281126)

  • 1. Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients with Obsessive-Compulsive Disorder.
    Umehara H; Numata S; Tajima A; Nishi A; Nakataki M; Imoto I; Sumitani S; Ohmori T
    PLoS One; 2016; 11(6):e0157232. PubMed ID: 27281126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
    de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
    Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
    Del Casale A; Sorice S; Padovano A; Simmaco M; Ferracuti S; Lamis DA; Rapinesi C; Sani G; Girardi P; Kotzalidis GD; Pompili M
    Curr Neuropharmacol; 2019; 17(8):710-736. PubMed ID: 30101713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.
    Diniz JB; Shavitt RG; Pereira CA; Hounie AG; Pimentel I; Koran LM; Dainesi SM; Miguel EC
    J Psychopharmacol; 2010 Mar; 24(3):297-307. PubMed ID: 19164490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.
    Sareen J; Kirshner A; Lander M; Kjernisted KD; Eleff MK; Reiss JP
    J Affect Disord; 2004 Oct; 82(2):167-74. PubMed ID: 15488245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
    Ramasubbu R; Ravindran A; Lapierre Y
    Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.
    Bloch MH; Storch EA
    J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):251-62. PubMed ID: 25791142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of treatment-resistant obsessive-compulsive disorder.
    Abudy A; Juven-Wetzler A; Zohar J
    CNS Drugs; 2011 Jul; 25(7):585-96. PubMed ID: 21699270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.